HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY (HRD) AS A PREDICTIVE BIOMARKER FOR TREATING CANCER WITH WEE1 INHIBITORS
Application
US20260083742A1
Kind: A1
Mar 26, 2026
Inventors
Jianhui Ma, Olivier Harismendy, Jiali Li, Ahmed Abdi Samatar, Samuel DePrimo, Catherine Lee, Monah Abed
Abstract
The present disclosure provides, among other things, methods for treating cancer comprising administering an effective dose of azenosertib, or a pharmaceutically acceptable salt thereof, to subjects selected to have a homologous recombination repair deficiency (HRD).
CPC Classifications
A61K 31/519
A61K 31/454
A61K 31/496
A61K 31/502
A61P 35/00
Filing Date
2025-12-01
Application No.
19404321